Hypolipidemic Effect of Lansiumamide B Obtained from Wampee Seeds in C57BL/6 Mice
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
The monomer lansiumamide B (LB) was obtained from wampee seeds by extraction, separation, and structural identification It was demonstrated through cell and mouse experiments that LB has a strong hypolipidemic effect in vivo and in vitro. The results showed that: LB could effectively inhibit the activities of α-amylase, α-glucosidase, and pancreatic lipase, with IC50 values of 18.43, 15.27, and 0.16 mg/mL, respectively. Acting on oleic acid (OA)-induced high-fat HepG2 cells, when the LB dose was 5 μg/mL, triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and malondialdehyde (MDA) contents decreased by 30.77%, 30.00%, 58.33%, 39.97%, 38.84%, and 43.90%, respectively. However, high-density lipoprotein cholesterol (HDL-C), catalase (CAT), and low-density lipoprotein receptor (LDLR) contents increased by 83.33%, 253.37%, and 60.97%, respectively. After 6 weeks of feeding high-fat mice with LB, their body weight significantly decreased compared with that of the high-fat control group (P<0.05). When a 60 mg/kg LB dose was provided, TC, TG, and LDL-C contents decreased by 29.18%, 23.69%, and 70.27%, respectively, and HDL-C content increased by 50.51%. The results showed that the four indices of body weight and blood lipids of high-fat mice were all well-controlled. These results suggest that LB is effective at reducing blood lipids in cells and in vivo, and is a potential dietary hypolipidemic compound.
